Earnings Call Insights: Qualys (QLYS) Q1 2026 Management View Sumedh Thakar (President, CEO & Director) tied product strategy to faster exploitation cycles, saying, "the number of detections is going to go up significantly while the exploit window is going to shrink dramatically" and positioning ETM as "the ETM enterprise TruRisk Management platform, which implements an AI ROC Risk Operation Cente...
Earnings Call Insights: Qualys (QLYS) Q1 2026 Management View Sumedh Thakar (President, CEO & Director) tied product strategy to faster exploitation cycles, saying, "the number of detections is going to go up significantly while the exploit window is going to shrink dramatically" and positioning ETM as "the ETM enterprise TruRisk Management platform, which implements an AI ROC Risk Operation Center so customers can get their risks remediated instead of relying on dashboard tourism with siloed products." Thakar highlighted exploit validation and remediation automation, stating, "Agent Val, is now Generally Available" and that ETM runs a closed loop that "detects vulnerabilities, validates exploit, quantifies real risk, automate remediation and revalidates the exploit." Thakar emphasized patching scale and reliability, citing "over 150 million patches deployed and over 40 million of these delivered autonomously in the last year" and adding that TruRisk Eliminate includes "our new AI-powered Patch Reliability Score" with "less than [ 0.10 % ] rollback rate." Thakar disclosed go-to-market and partnership developments, including "nearly 2 dozen certified mROC partners" and partnerships "with OpenAI in their Trusted Access for Cyber program and with Anthropic in their Cyber Verification Program," plus "a new strategic partnership with Converge Insurance" tied to Qualys ETM for premium reduction qualification. Joo Mi Kim (CFO & Principal Accounting Officer) reported, "Revenues grew 10% to $175.6 million" and said partner-led motion continued with "52% of total revenue" from channel, as "Revenues from channel partners grew 17%, outpacing direct, which grew 3%." Outlook The analysts estimates JSON provided in the prompt does not match the required fiscalQuarter formatting (Q1-Q4) and is not used for any comparisons in this summary. Kim raised full-year revenue guidance, stating, "For the full year 2026, we now expect revenues to be in the range of $721 million to $727 millio...
Earnings Call Insights: Genworth Financial (GNW) Q1 2026 Management view "In the first quarter, we continue to execute across our strategic priorities, Enact once again generated strong shareholder value. We advanced our long-term growth strategy through CareScout, and we further strengthened the self-sustainability of our Closed Block." (President, CEO & Director Thomas McInerney) "Going forward,...
Earnings Call Insights: Genworth Financial (GNW) Q1 2026 Management view "In the first quarter, we continue to execute across our strategic priorities, Enact once again generated strong shareholder value. We advanced our long-term growth strategy through CareScout, and we further strengthened the self-sustainability of our Closed Block." (President, CEO & Director Thomas McInerney) "Going forward, we will report Genworth's consolidated adjusted operating income, excluding the Closed Block." (President, CEO & Director McInerney) He also said the company reported "net income of $47 million" and "adjusted operating income, excluding the Closed Block of $109 million," with Enact delivering "adjusted operating income of $140 million" and holding company liquidity of "$166 million of cash and liquid assets." (President, CEO & Director McInerney) "Since the initial authorization of our current buyback program, we have bought back a total of $875 million worth of shares at an average price of $6.38 as of April 30." (President, CEO & Director McInerney) "By the end of 2026, we anticipate having more than 1,000 home care locations and approximately 2,000 senior living communities as part of the CQN." (President, CEO & Director McInerney) He added, "We facilitated approximately 1,500 matches between care seekers and providers in the first quarter" and said the company remains on track for "approximately 7,500 matches in 2026 compared to 3,255 matches in 2025." (President, CEO & Director McInerney) "As Enact announced yesterday, it has increased its quarterly dividend and continues to expect to return approximately $500 million of capital to its shareholders in 2026." (Executive VP & CFO Jerome Upton) Outlook "Based on our approximate 81% ownership position, we continue to expect to receive around $405 million from Enact for the full year." (Executive VP & CFO Upton) "For the full year 2026, we now expect to allocate between $195 million and $225 million to share repurchases." ...
Earnings Call Insights: Royalty Pharma (RPRX) Q1 2026 Management View "I am happy to report a strong start to 2026 as we execute towards our goal to be the premier capital allocator in life sciences, with consistent compounding growth." (Founder, Chairman of the Board & CEO Pablo Legorreta) "We delivered 10% growth in portfolio receipts, our top line and 13% growth in royalty receipts, which are o...
Earnings Call Insights: Royalty Pharma (RPRX) Q1 2026 Management View "I am happy to report a strong start to 2026 as we execute towards our goal to be the premier capital allocator in life sciences, with consistent compounding growth." (Founder, Chairman of the Board & CEO Pablo Legorreta) "We delivered 10% growth in portfolio receipts, our top line and 13% growth in royalty receipts, which are our recurring cash flows." (CEO Legorreta) "We had a busy quarter with $1.25 billion of announced transactions on 3 attractive therapies, while capital deployed was in excess of $0.5 billion." (CEO Legorreta) "We also repurchased 1 million shares for $50 million in the quarter and increased our dividend by 7%." (CEO Legorreta) "In the first quarter alone, we signed deals with J&J and Teva totaling $1 billion in announced value." (Chairman of Partnering & Investments Christopher Hite) "We provided $250 million upfront in return for 30% of their royalty on Jazz and BeOne's Ziihera, which translates to a low to mid-single-digit royalty for Royalty Pharma." (Executive Vice President of Research & Investments Marshall Urist) "Royalty receipts grew by 13% in the first quarter, reflecting the strength of our diversified portfolio." (Executive VP & CFO Terrance Coyne) Outlook "We are raising our full year 2026 financial guidance." (Executive VP & CFO Coyne) "We now expect portfolio receipts to be in the range of $3.325 billion to $3.45 billion, up from $3.275 billion to $3.425 billion previously." (CFO Coyne) "This assumes growth in royalty receipts of around 4% to 8%." (CFO Coyne) "Given these dynamics, we are providing guidance for the second quarter portfolio receipts, which we expect to be between $740 million and $760 million." (CFO Coyne) "This assumes" impacts including "the loss of exclusivity for Promacta" and "the launch of biosimilar Tysabri in the United States" plus "the potential impact of IRA." (CFO Coyne) Financial Results "Operating and professional costs were 3.9% ...
Moon Safari/iStock via Getty Images Alcon ( ALC ) declined more than 10% on Wednesday after posting a mixed first-quarter print where revenue missed analysts’ consensus by $10M. The stock was trading 10.58% lower at $66.25 during midday trading. The Swiss eye-care firm posted earnings of $0.85 per share and revenue of $2.7B. The company attributed the first-quarter performance to its new product l...
Moon Safari/iStock via Getty Images Alcon ( ALC ) declined more than 10% on Wednesday after posting a mixed first-quarter print where revenue missed analysts’ consensus by $10M. The stock was trading 10.58% lower at $66.25 during midday trading. The Swiss eye-care firm posted earnings of $0.85 per share and revenue of $2.7B. The company attributed the first-quarter performance to its new product launches, including Unity VCS and CS, PanOptix Pro, Tryptyr and Precision7. Surgical net sales, which include implantables, consumables and equipment/other, were $1.5 billion, representing a 10% year-on-year increase. Vision Care net sales, which include contact lenses and ocular health, came in at $1.2 billion, a 9% year-on-year jump. Operating income declined 38% to $292 million, while operating margin fell 8.2 percentage points. “The current year period included costs associated with efficiency initiatives, impairment charges related to an intangible asset, incremental tariffs, sales and marketing behind new product launches and increased research and development,” the company said. The company increased its core EPS growth outlook for 2026 in the range of 10% to 13%. It continues to see net sales growth between 5% and 7% and core operating margin growth within 70 bps to 170 bps. As per Seeking Alpha, the FY26 revenue consensus is $11.13B, while that for EPS is $3.44. Alcon also announced a buyback program under which it will repurchase up to $1.5 billion of the company’s common shares, par value of CHF 0.04 per share. More on Alcon Alcon And LENSAR: Why The Broken Merger Creates Two Different Buy Cases Alcon Buy Rating Reaffirmed, Despite Failed STAAR Merger, As Eyecare Portfolio Leads Alcon Inc. (ALC) Q4 2025 Earnings Call Transcript Alcon Non-GAAP EPS of $0.85 beats by $0.03, revenue of $2.7B misses by $10M Alcon Q1 2026 Earnings Preview
ABBPhoto/iStock via Getty Images Super Micro Computer ( SMCI ) is up over 17% in premarket trading on Wednesday after the company reported 3Q26 earnings on Tuesday after the bell. Going into earnings, the stock was down over 33% over the past 6 months and down over 54% since its all-time high at $62 back in July of last year. Seeking Alpha After a series of unfortunate events, the market lost conf...
ABBPhoto/iStock via Getty Images Super Micro Computer ( SMCI ) is up over 17% in premarket trading on Wednesday after the company reported 3Q26 earnings on Tuesday after the bell. Going into earnings, the stock was down over 33% over the past 6 months and down over 54% since its all-time high at $62 back in July of last year. Seeking Alpha After a series of unfortunate events, the market lost confidence in the company, especially following the legal issues surrounding former senior executive Wally Liaw, who was indicted in connection with alleged export control violations involving the diversion of SMCI products to China. Layered on top of the residual scar tissue from the Hindenburg short report, the Ernst & Young auditor resignation, and the 10-K filing delay saga that defined late 2024, SMCI had become a case study in how quickly an AI infrastructure darling can be re-rated when governance overhangs compound on top of one another. Heading into Tuesday's print, the buyside was arguably more focused on damage assessment than on the underlying operating story. But, against all odds, the company delivered, and the pullback we saw from all-time highs and even over the past months shows that the market has long priced in the negatives. I last covered the stock in late April, and following my sell, the stock dipped as much as 10% but later slightly recovered to the $27 level, that is, until earrings. When I downgraded SMCI to a sell following the BlueFin Research note on the alleged Oracle ( ORCL ) contract cancellation, my sell was driven by three structural concerns: customer concentration of roughly 63% from a single hyperscaler, gross margin compression to 6.4% non-GAAP in 2Q26, and the governance overhang from the Liaw indictment leaking into customer relationships and Nvidia ( NVDA ) allocation. I said at the time that I would consider an upgrade back to a buy "if management shows sustainability of the contracts with other customers." The 3Q print answered all thr...
Logistics complicated for 30 May showpiece in Budapest Arsenal to receive only 16,824 official ticket allocation Arsenal have had to find different ways to win this season as they pursue a Premier League and Champions League double . Their fans will now have to show similar dexterity if they hope to make it to Budapest for Uefa’s showpiece final. With direct flights from London costing up to £1,50...
Logistics complicated for 30 May showpiece in Budapest Arsenal to receive only 16,824 official ticket allocation Arsenal have had to find different ways to win this season as they pursue a Premier League and Champions League double . Their fans will now have to show similar dexterity if they hope to make it to Budapest for Uefa’s showpiece final. With direct flights from London costing up to £1,500 and the only available hotel rooms some 20 miles from the Hungarian capital, it could be the most expensive Champions League final to attend in history. But with a bit of luck and logistical flexibility (and the ability to stay awake all night), Gunners supporters can still hope to match Declan Rice’s demand that 200,000 descend upon the Danube at the end of this month. Continue reading...
Bernstein analyst Peter Weed raised his price target on ServiceNow (NYSE:NOW) to $236 from $226 while maintaining an Outperform rating, framing the company’s Analyst Day as a long-term margin and free cash flow win. The catch: the same event armed the bears with a 2030 subscription revenue target of $30 billion that implies growth decelerating ... Bernstein Hikes ServiceNow Price Target to $236: W...
Bernstein analyst Peter Weed raised his price target on ServiceNow (NYSE:NOW) to $236 from $226 while maintaining an Outperform rating, framing the company’s Analyst Day as a long-term margin and free cash flow win. The catch: the same event armed the bears with a 2030 subscription revenue target of $30 billion that implies growth decelerating ... Bernstein Hikes ServiceNow Price Target to $236: Was the Analyst Day a Win or a Trap?
Wachiwit/iStock Editorial via Getty Images Apple Inc. ( AAPL ) has had a very strong quarter, with promising implications for its near-term and long-term growth. The China rebound and India's double-digit growth are not one-time tailwinds, and the memory shortage may have been a headwind, but it also has some favorable implications. Though there are some risks that you should know, the near-term a...
Wachiwit/iStock Editorial via Getty Images Apple Inc. ( AAPL ) has had a very strong quarter, with promising implications for its near-term and long-term growth. The China rebound and India's double-digit growth are not one-time tailwinds, and the memory shortage may have been a headwind, but it also has some favorable implications. Though there are some risks that you should know, the near-term and long-term opportunities are significant and should continue to deliver value to shareholders. The reaction to the Q2 results was positive. After the company announced them, the buyers drove the price outside the upper Bollinger band (2.5σ, 50DMA) before normalizing. TrendSpider That is consistent with the growth and guidance. First of all, total revenue came in at $111.18 billion , up 16.6% YoY. The sequential decline of 22.7% was largely expected, coming from the holiday quarter. iPhone revenue, 51.3% of total, increased by 21.7% YoY to $56.99 billion. That is the highlight, and the market probably liked the fact that the supply constraint Apple faced prevented the result from being as good as it should have been, even adjusting for the FX tailwind. Services revenue grew 16.3% YoY to $30.98 billion, and that also helped with sentiment, as it's a significant revenue contributor at 27.9% of total revenue and a meaningful contributor to Apple's 49.3% gross margin. Mac, iPad, and Wearables/Home/Accessories grew by 5.7%, 8%, and 5% YoY, respectively. These are not large contributors to revenue, but the latest report showed that the business growth is broad-based. The gross margin of 49.3% is up 222 bps YoY, which frankly is extraordinary for a hardware company facing rising memory and component costs. Operating income increased by 21.3% and diluted EPS grew 21.8%. Greater China revenue jumped by 28.1% from the second quarter a year ago to $20.5 billion, marking its second consecutive quarter of strong growth after years of slow expansion. An explanation for the rebound is gi...
Wachiwit/iStock Editorial via Getty Images Apple Inc. ( AAPL ) has had a very strong quarter, with promising implications for its near-term and long-term growth. The China rebound and India's double-digit growth are not one-time tailwinds, and the memory shortage may have been a headwind, but it also has some favorable implications. Though there are some risks that you should know, the near-term a...
Wachiwit/iStock Editorial via Getty Images Apple Inc. ( AAPL ) has had a very strong quarter, with promising implications for its near-term and long-term growth. The China rebound and India's double-digit growth are not one-time tailwinds, and the memory shortage may have been a headwind, but it also has some favorable implications. Though there are some risks that you should know, the near-term and long-term opportunities are significant and should continue to deliver value to shareholders. The reaction to the Q2 results was positive. After the company announced them, the buyers drove the price outside the upper Bollinger band (2.5σ, 50DMA) before normalizing. TrendSpider That is consistent with the growth and guidance. First of all, total revenue came in at $111.18 billion , up 16.6% YoY. The sequential decline of 22.7% was largely expected, coming from the holiday quarter. iPhone revenue, 51.3% of total, increased by 21.7% YoY to $56.99 billion. That is the highlight, and the market probably liked the fact that the supply constraint Apple faced prevented the result from being as good as it should have been, even adjusting for the FX tailwind. Services revenue grew 16.3% YoY to $30.98 billion, and that also helped with sentiment, as it's a significant revenue contributor at 27.9% of total revenue and a meaningful contributor to Apple's 49.3% gross margin. Mac, iPad, and Wearables/Home/Accessories grew by 5.7%, 8%, and 5% YoY, respectively. These are not large contributors to revenue, but the latest report showed that the business growth is broad-based. The gross margin of 49.3% is up 222 bps YoY, which frankly is extraordinary for a hardware company facing rising memory and component costs. Operating income increased by 21.3% and diluted EPS grew 21.8%. Greater China revenue jumped by 28.1% from the second quarter a year ago to $20.5 billion, marking its second consecutive quarter of strong growth after years of slow expansion. An explanation for the rebound is gi...
Northcoast Research has pulled Norwegian Cruise Line (NYSE:NCLH) from its Buy list, downgrading the stock to Neutral on May 6. The firm cited a slower-than-expected balance sheet transformation and an industry backdrop made worse by the war in Iran. The analyst downgrade lands one day after price target cuts from Goldman Sachs, Morgan Stanley, Barclays, ... Northcoast Just Yanked Norwegian Cruise ...
Northcoast Research has pulled Norwegian Cruise Line (NYSE:NCLH) from its Buy list, downgrading the stock to Neutral on May 6. The firm cited a slower-than-expected balance sheet transformation and an industry backdrop made worse by the war in Iran. The analyst downgrade lands one day after price target cuts from Goldman Sachs, Morgan Stanley, Barclays, ... Northcoast Just Yanked Norwegian Cruise Line From Its Buy List: Iran War Sinks the Cruise Industry
Tesla ramps capex beyond $25B to fuel AI, robotics, and autonomy bets, but rising risks, negative cash flow, and unclear timelines cloud near-term outlook.
Tesla ramps capex beyond $25B to fuel AI, robotics, and autonomy bets, but rising risks, negative cash flow, and unclear timelines cloud near-term outlook.